SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Brooks Laboratories shines on commencing commercial production at manufacturing unit-II in Vadodara

07 Mar 2017 Evaluate

Brooks Laboratories is currently trading at Rs. 146.40, up by 8.65 points or 6.28 % from its previous closing of Rs. 137.75 on the BSE.

The scrip opened at Rs. 138.00 and has touched a high and low of Rs. 149.65 and Rs. 138.00 respectively. So far 90493 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 194.40 on 01-Nov-2016 and a 52 week low of Rs. 72.00 on 24-Jun-2016.

Last one week high and low of the scrip stood at Rs. 149.65 and Rs. 137.00 respectively. The current market cap of the company is Rs. 235.84 crore.

The promoters holding in the company stood at 60.62%, while Institutions and Non-Institutions held 0.28% and 39.11% respectively.

Brooks Laboratories has commenced commercial production at its New Manufacturing Unit-II, Vadodara, Gujarat. The company’s Vadodra facility had received manufacturing licence from Commissioner of Food & Drugs Control Administration, Gandhinagar last year, valid for the period of 5 years from August 16, 2016 to August 15, 2021.

Brooks Laboratories is a Research and Development driven Pharmaceutical manufacturing company, in last 6 years company has successfully established itself as a reputed Contract Manufacturing company for latest molecules in Injectables and Clavulanic Acid range in Tablets and Dry Syrups.

Brooks Laboratories Share Price

64.77 3.08 (4.99%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×